Table 5 Demographic data for the discovery study.
| Â | OAG | Control | P value |
|---|---|---|---|
No. of eyes | 40 | 37 | Â |
Age (years)†| 64.3 ± 11.6 | 66.6 ± 7.1 | 0.2928 |
Laterality (right:left)‡ | 17:23 | 23:14 | 0.1113 |
Sex (male:female)‡ | 21:19 | 17:20 | 0.6505 |
IOP (mmHg)†| 18.1 ± 6.2 | 13.7 ± 3.3 | 0.0003 |
BCVA (logMAR)†| 0.39 ± 0.57 | 0.58 ± 0.42 | 0.1023 |
Axial length (mm)†| 24.9 ± 1.6 | 24.0 ± 1.6 | 0.0153 |
Glaucoma medications, n (%) | Â | Â | Â |
Prostaglandin analogs | 39 (97.5) | 0 (0) | Â |
β-blockers | 35 (87.5) | 0 (0) |  |
Carbonic anhydrase inhibitors (eye drop) | 31 (77.5) | 0 (0) | Â |
Carbonic anhydrase inhibitors (dose) | 15 (37.5) | 0 (0) | Â |
α-2 stimulates | 32 (80.0) | 0 (0) |  |
Rho-kinase inhibitors | 15 (37.5) | 0 (0) | Â |